IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 601 
Recognizing the duty of the Federal Government to lead the world in 
biomedical research. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 23, 2025 
Ms. DEGETTE (for herself, Mr. RASKIN, and Mr. AUCHINCLOSS) submitted 
the following resolution; which was referred to the Committee on Energy 
and Commerce 
RESOLUTION 
Recognizing the duty of the Federal Government to lead 
the world in biomedical research. 
Whereas the model of Federal Government funding to sup-
port free scientific inquiry in partnership with academia 
and industry since World War II has produced an un-
precedented increase in knowledge about medicine and 
the human body; 
Whereas the National Institutes of Health has grown from a 
single laboratory at its founding in 1887 to the world’s 
leading grant-making agency and crown jewel of bio-
medical progress as the world’s largest single public 
funder of biomedical and behavioral research; 
Whereas the Federal Government’s unprecedented investment 
in research to solve military medical challenges in World 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
War II directly led to breakthroughs such as large-scale 
penicillin production, ushered in a golden age of drug de-
velopment, and provided the foundation for the National 
Institutes of Health extramural research program; 
Whereas the funds of the National Institutes of Health sup-
port basic research that enables downstream scientific 
breakthroughs but that cannot be replicated in private 
settings, as this research often cannot be directly mone-
tized into a marketable good or service or is considered 
too early-stage, too risky, or too complex for industry in-
vestment; 
Whereas research supported by the National Institutes of 
Health has underpinned nearly every new drug approved 
by the Food and Drug Administration in the 21st cen-
tury; 
Whereas federally funded research into the hepatitis C virus 
paved the way for direct-acting antivirals that cure a pre-
viously life-threatening disease in 95 percent of cases; 
Whereas the death rate for HIV/AIDS has decreased from a 
peak of 16.2 per 100,000 in 1995 to 1.4 per 100,000 
today, and 50 drugs are now available to manage HIV; 
Whereas National Institutes of Health research has improved 
understanding of the causes, prevention, and treatment 
of heart disease, leading in part to a reduction in the 
death rate from heart disease from 307 per 100,000 in 
1950 to 135 per 100,000 in 1996, and decreased rates 
of stroke by 70 percent in this same period; 
Whereas the National Institutes of Health’s more than 
$8,000,000,000 annual investment in cancer research 
generates $69,000,000,000 in annual economic activity 
and 7,000,000 jobs, and has fueled a reduction in the 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
cancer death rate in the United States by 34 percent 
from 1991 to 2022, averting approximately 4,500,000 
deaths; 
Whereas research funded by the United States Government 
over 35 years prior to the COVID–19 pandemic led to 
the capability of developing and delivering effective vac-
cines in under 1 year; 
Whereas the Human Genome Project launched the genomic 
revolution while producing $796,000,000,000 in economic 
returns for an investment of only $3,800,000,000, a re-
turn on investment of $209 for every $1 invested, and 
the All of Us Research Program will enable a further rev-
olution in precision medicine; 
Whereas federally supported research led to the recent devel-
opment and use of a miraculous personalized gene-editing 
therapy to treat an infant with a rare, incurable disease, 
making history and laying the groundwork to rapidly de-
velop treatments for other rare genetic diseases; 
Whereas researchers in America, due to scientific workforce 
breated by public investment, are uniquely positioned to 
address major challenges in public health and medicine, 
including— 
(1) an aging population, with nearly 58,000,000 
Americans age 65 or older and increasing; 
(2) approximately 6 in 10 Americans have at least 
1 chronic disease; 
(3) more than 90 percent of the Nation’s 
$4,500,000,000,000 in annual health care expenditures 
go to treat individuals with chronic diseases and mental 
health conditions; 
(4) over 2,800,000 antibiotic resistant infections 
occur in the United States annually; 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
(5) approximately 945,000 Americans die of heart 
disease or stroke each year; 
(6) approximately 2,000,000 Americans are diag-
nosed with cancer each year and over 600,000 Americans 
die from cancer each year; 
(7) over 38,000,000 Americans have diabetes, and 
over 98,000,000 Americans have prediabetes; and 
(8) nearly 7,000,000 Americans have Alzheimer’s 
disease; 
Whereas the Trump administration has reduced the bio-
medical research capacity of the United States and put 
the United States at risk of losing a generation of sci-
entific talent; 
Whereas the Trump administration at its outset halted Na-
tional Institutes of Health advisory councils and study 
sections, effectively freezing new grantmaking activities; 
Whereas the Trump administration implemented a commu-
nications freeze at the Department of Health and Human 
Services, preventing researchers at National Institutes of 
Health Clinical Center from meeting with patient groups 
or recruiting patients for clinical trials of new therapies; 
Whereas the Trump administration’s ban on research in col-
laboration with international partners or involving topics 
deemed disfavored led to the illegal termination or delay 
of nearly 2,500 meritorious grants at the National Insti-
tutes of Health in the first 4 months of the administra-
tion; 
Whereas the Trump administration fired thousands of em-
ployees supporting critical biomedical research at the De-
partment of Health and Human Services, including at 
the National Cancer Institute, where the administration 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6300
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
fired staff responsible for disseminating new evidence on 
cancer treatment and diagnosis, leaving doctors and pa-
tients to access outdated information, and delaying sci-
entific progress toward finding new treatments and cures; 
Whereas the Trump administration has proposed cutting 
funding for the National Institutes of Health by 40-per-
cent and reducing its 27 Institutes and Centers to just 
8, which would significantly undermine the abilities of the 
Institutes to effectuate their core scientific missions and 
decimate progress toward understanding and treating dis-
ease; 
Whereas the Congressional Budget Office has found that a 
10-percent funding reduction for the National Institutes 
of Health would result in 2 fewer drugs coming to mar-
ket each year; 
Whereas the Trump administration has, for the first time in 
National Institutes of Health’s history, placed political 
appointees in positions other than the Director and the 
Director of the National Cancer Institute, including with-
in the National Institutes of Health’s Institutes and Cen-
ters, threatening the independence of the National Insti-
tutes of Health scientific decision making, and risking 
the American people’s trust in the National Institutes of 
Health’s investments, statements, and advice; 
Whereas the Trump administration is purging scientists who 
are seen as insufficiently aligned with the administra-
tion’s views from National Institutes of Health processes; 
Whereas the Trump administration has halted funding allo-
cated to leading academic research institutions for life-
saving research as leverage to achieve unrelated policy 
VerDate Sep 11 2014 
23:06 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6300
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
objectives, thereby halting or delaying ongoing biomedical 
research projects; and 
Whereas the actions of the Trump administration have led 
our adversaries to attempt to entice our researchers and 
scientists to leave our shores and relocate abroad: Now, 
therefore, be it 
Resolved, That it is the sense of the House of Rep-
resentatives that— 
(1) the biomedical research of the United States 
and development capacity is a national asset that 
must be protected, improved, and expanded; 
(2) Federal Government efforts through the 
National Institutes of Health ensure a robust bio-
medical research apparatus and support the global 
role of the United States as a leader of biomedical 
advancement and innovation; 
(3) the biomedical research workforce of the 
United States, including the public servants at the 
National Institutes of Health and other Federal 
agencies, should be treated with respect, and the 
jobs associated with biomedical research should offer 
good pay and benefits; 
(4) protecting public health must be a whole-of- 
government collaboration beginning with the re-
search necessary to advance public health; 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
(5) Federal Government support is integral 
to— 
(A) training new scientists in varied public 
health and research disciplines; 
(B) encouraging and facilitating premier 
scientists to stay in the United States for their 
careers; 
(C) ensuring a robust field of scientists in 
the United States who are committed to the ad-
vancement of science, public health, and bio-
medicine; and 
(D) stability of biomedical research fund-
ing so that United States-based researchers are 
focused on science and advancement rather 
than administrative burdens or political inter-
ference; 
(6) scientific decision making in the Federal 
Government should be driven by the best available 
evidence, effectuated by peer-reviewed scientists, and 
insulated from political interference; 
(7) over the next decade, the Federal Govern-
ment should double its investment in biomedical re-
search and properly applying the findings of bio-
medical research to medical practice; 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
(8) Federal biomedical research investments 
should— 
(A) support basic research that improves 
our understanding of the human body in all its 
diversity, and how external factors such as life-
style factors, social factors, and environmental 
factors affect its function; 
(B) support research that seeks to clarify 
the root causes of diseases; 
(C) support translational science that ac-
celerates access of Americans to novel treat-
ments; 
(D) support potentially transformative 
high-risk, high-reward research; 
(E) support and enable collaborative, 
broad-based resources that may be used across 
different researchers and institutions; 
(F) support and enable research collabora-
tion across individual researchers and institu-
tions and facilitate knowledge sharing; 
(G) serve a dual mandate of increasing un-
derstanding of a particular scientific question 
and increasing the capacity of funded research-
ers and institutions to perform future research 
of value; 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
(H) support transparency, accountability, 
and replicability in innovative biomedical re-
search; 
(I) support novel processes, products, and 
other innovations that have the potential to pre-
vent, mitigate, or cure disease, particularly 
those which may reduce overall health care ex-
penditures; and 
(J) support the integration of evidence 
generated by biomedical research into clinical 
practice, including by expanding partnerships 
with Federal health agencies, health profes-
sionals, patients, health systems, payors, indus-
try, and community-based organizations; and 
(9) it should be the policy of the Federal Gov-
ernment to invest in research with the potential to 
improve the quality of life for all Americans and in-
novations in medicine, including— 
(A) reversing the recent decline in United 
States life expectancy; 
(B) developing technologies to ensure the 
ability to prevent and respond to microbial 
threats to humans and animals; 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
(C) identifying the underlying causes of 
neurogenerative diseases and developing tools to 
reduce the burden of such diseases; 
(D) reducing the death rate from cancer 
and improving the quality of life of those diag-
nosed with cancer; 
(E) reducing the burden of Alzheimer’s 
disease and related dementias, including by de-
veloping evidence-based tools to effectively pre-
vent Alzheimer’s disease; 
(F) reducing the number of people who die 
waiting for transplantable organs to zero; 
(G) avoiding preventable diabetes diag-
noses; 
(H) reducing deaths from cardiovascular 
disease, including stroke; 
(I) developing versatile therapeutic plat-
forms that can be repurposed for various appli-
cations, including treatments for ultrarare ge-
netic diseases; 
(J) developing effective interventions to 
prevent and treat chronic symptoms of viral 
and bacterial infections, including COVID–19, 
Lyme disease, and Epstein-Barr virus; 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 601 IH 
(K) developing effective preventive vaccines 
and therapeutics for diseases that have histori-
cally affected underserved populations world-
wide and attracted lower levels of investment, 
such as chikungunya, dengue, and malaria; and 
(L) improving representation in clinical 
trials to ensure broad applicability of scientific 
findings and improve the health of underserved 
populations. 
Æ 
VerDate Sep 11 2014 
17:42 Jul 24, 2025
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6301
E:\BILLS\HR601.IH
HR601
ssavage on LAPJG3WLY3PROD with BILLS